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Background: Platelets are frequently altered in hepatocellular carcinoma (HCC) patients. Platelet lysates (hPL) can
enhance HCC cell growth and decrease apoptosis. The aims were to evaluate whether hPL can modulate the
actions of Sorafenib or Regorafenib, two clinical HCC multikinase antagonists.
Methods: Several human HCC cell lines were grown in the presence and absence of Sorafenib or Regorafenib, with
or without hPL. Growth was measured by MTT assay, apoptosis was assessed by Annexin V and by western blot,
and autophagy and MAPK growth signaling were also measured by western blot, and migration and invasion were
measured by standard in vitro assays.
Results: Both Sorafenib and Regorafenib-mediated inhibition of cell growth, migration and invasion were all
antagonized by hPL. Drug-mediated apoptosis and decrease in phospho-ERK levels were both blocked by hPL,
which also increased anti-apoptotic phospho-STAT, Bax and Bcl-xL levels. Preliminary data, obtained with epidermal
growth factor (EGF) and insulin-like growth factor-I (IGF-I), included in hPL, revealed that these factors were able to
antagonized Sorafenib in a proliferation assay, in particular when used in combination.
Conclusions: Platelet factors can antagonize Sorafenib or Regorafenib-mediated growth inhibition and apoptosis in
HCC cells. The modulation of platelet activity or numbers has the potential to enhance multikinase drug actions.
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Platelet activity has been known for a long time to be al-
tered in the presence of cancer, with venous thrombosis
being recognized in association with occult malignancy
[1,2]. In addition to the effects of cancer on platelet
actions in blood clotting, platelets have been recognized
to be involved in cancer development, progression and
metastasis [3-8]. Platelet levels have been shown to im-
pact prognosis in several cancers, including those of the
ovary, kidney, colon, lung and pancreas [9-14]. Further-
more, whereas hepatocellular carcinoma (HCC) most typ-
ically arises on the basis of cirrhosis, with its frequently
associated splenomegaly and thrombocytopenia, normal* Correspondence: brianicarr@hotmail.com
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article, unless otherwise stated.or elevated platelet levels are frequently seen in large size
HCCs [15-17]. We recently found that platelet extracts
can stimulate HCC cell line growth in vitro, which was as-
sociated with a decrease in apoptosis [18]. We now extend
those observations, by examining the effects of platelet ex-
tracts on the effects of apoptosis-inducing HCC treatment
agents and report that platelet extracts can antagonize
growth inhibition mediated by Sorafenib or Regorafenib.Methods
Cells and materials
PLC/PRF/5, Hep3B and HepG2 cells were obtained from
the ATCC and were cultured as previously described [19].
Recombinant human EGF was purchased from Pepro-
Tech (Rocky Hill, NJ, USA), mouse recombinant IGF-I
from Calbiochem (San Diego, CA, USA) and serotoninentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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growth factors were dissolved in water.
Platelet lysates
The platelet samples were collected from healthy volun-
teers. The study protocol was approved by the institutional
review boards of the University of Bari and “Saverio de
Bellis” Institute of Castellana G. (BA), Italy. Additionally,
written informed consent was obtained from participants
for the use of their blood in this study.
The platelet-rich plasma was obtained using an auto-
mated hemapheresis procedure in a local blood transfusion
center. The platelets obtained from different volunteers
were mixed and then divided into aliquots. Each aliquot
was subjected to several freeze-thaw cycles to disrupt their
membranes and release the growth factors stored in the
granules (human Platelet Lysate, hPL).
Growth assay
Proliferation assay was performed as recently described
[19,20]. The cells were cultured in 1% FBS medium con-
taining different hPL concentrations (2.5 - 3.75 × 107) or
equivalent percentage of FBS in presence of 1 μM
(HepG2 cell line) or 2.5 μM (Hep3B and PLC/RFP/5) of
Sorafenib or Regorafenib. In the same growth condition
HCC cell lines were cultured in presence of EGF 10,
25 mg/ml, IGF-I 50, 100 mg/ml and serotonin 1, 10 μM
with or without Sorafenib 1 μM.
AFP measurement
Medium AFP levels were measured using an auto-
mated system (UniCel Integrated Workstations DxC 660i,
Beckman Coulter, Fullerton, CA, USA) by a chemolu-
minescent immunometric method. Sample measurements
over the calibration range were automatically re-analyzed
according to manufacture’s instructions.
Migration assay
A scratch assay was performed as previously described
[19,20]. Briefly, a wound was generated with a pipette tip,
after rinsing, medium containing different concentrations
of hPL or equivalent percentage of FBS and 2.5 μM
Sorafenib or Regorafenib was added. Photographs were
taken of each well immediately and after 24 h and 48 h.
The values were expressed as percentage of migration,
with 100% being when the wound was completely closed.
The results were representative of three independent
experiments.
Invasion assay
Cell invasion assays were performed using Matrigel (BD
Transduction, San Jose, CA, USA)-coated Transwells
(8 μm pore PET membrane, Millipore, Billerica, MA,
USA) as previously described (19). Briefly, 2.5 μMSorafenib or Regorafenib treated cells were suspended in
low serum medium. Medium containing different hPL
or FBS concentrations was added to the bottom wells.
After incubation of 24 h, the invading cells were fixed
and stained. The images were acquired and analyzed
counting the cells with Image J Software (National Insti-
tute of Health, USA). Values obtained were expressed as
fold increase of invading cells, setting the cell counts of




The Muse Annexin V/Dead Cell Assay Kit (Millipore,
Darmstadt, Germany) for quantitative analysis of live, early/
late apoptotic and dead cells was used with a Muse Cell
Analyzer (Millipore). Briefly, the assay utilizes Annexin V
to detect PS on the external membrane of apoptotic cells.
A dead cell marker (7-AAD) is also used. PLC/PRF/5 cell
line, including positive and negative controls, were cul-
tured in 1% FBS medium supplemented with a volume of
hPL corresponding to 3.75 × 107 platelets/ml or with an
equivalent percentage of serum (control cells) for 48 h.
The cells were then processed as described in the user’s
guide.
Caspase-3/7 quantitative measurements
The Muse Caspase-3/7 kit (Millipore) permits simultan-
eous evaluation of apoptotic status based on Caspase-3
and −7 activation and cellular plasma membrane
permeabilization (cell death). The assay provides rela-
tive percentage of cells that are live, early/late apoptotic
or dead. Cells were cultured as described above and
processed according to the user’s guide.
Western blots
We analyzed the MAPK signaling and anti-apoptosis
markers in Hep3B cells treated with 2.5 μM Sorafenib or
Regorafenib and hPL by Western blot, as previously de-
scribed [19,20]. In brief, cells were washed twice with cold
PBS and then lysed in RIPA buffer (Sigma-Aldrich, Milan;
Italy). After quantization of protein concentration, equal
amount of protein (50 μg) were resolved on SDS–PAGE
and transferred to polyvinyldifluoride (PVDF) filters. The
blots were blocked with 5% (w/v) nonfat dry milk for 2 h
at room temperature and then probed with primary anti-
body overnight at 4°C.
The primary antibodies were directed against the
following proteins: ERK and phospho-ERK (P-ERK), JNK
and phospho-JNK (P-JNK), p38 and phospho-p38 (P-p38),
STAT3 and phospho-STAT3 (Tyr705, Ser727) (P-STAT3),
AKT and phospho-AKT (P-AKT), survivin, Bcl-xL, Bax,
Bim and β-actin (Cell Signaling, Beverly, MA, USA). After
three washes, incubation was followed by the reaction with
Figure 1 (See legend on next page.)
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Figure 1 Platelets antagonism of Sorafenib or Regorafenib mediated cell growth inhibition. Hep3B (A, B), PLC/PRF/5 (C, D) and HepG2
(E, F) cell lines were cultured in 1% FBS medium in presence of different platelet concentrations or FBS and incubated with 1–2.5 μM Sorafenib
(A, C, E) or Regorafenib (B, D, F). MTT assay was assessed after 24-72 h. (G) MTT assay performed on PLC/RFP/5 cells treated or untreated with
2.5 μM Regorafenib and cultured in different FBS concentrations (0-5%) for 48 h in presence or absence of hPL derived from 3.75 × 107 platelets.
(H) AFP levels in the cell culture medium of PLC/PRF/5 cell lines containing hPL or FBS after treatment with different Sorafenib concentrations.
The results are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001.
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1 h at room temperature. The immunoreactive bands were
visualized and analyzed using the enhanced chemilumi-
nescence detection reagents (Cell Signaling), according to
the manufacturer’s instructions, and chemiluminescence
detection system (ChemiDoc XRS apparatus and software,
Bio-Rad).
Statistical analysis
GraphPad Prism 5.0 software (La Jolla, CA, USA) was
used for all statistical analysis. Mann–Whitney nonpara-
metric test was employed to assess the statistical signifi-
cance of differences between two groups. For multiple
comparisons was used one-way Anova test followed by
appropriate post-test. P-values of <0.05 were considered
statistically significant. All experiments were done in
triplicate and data are presented as mean ± standard
deviation (SD).
Results
Platelet factors antagonize drug-mediated inhibition of
HCC cell growth
hPL were previously examined for the ability to stimulate
human HCC cell line growth [18]. Hep3B, PLC/PRF/5 and
HepG2 human HCC cell lines were treated in log phase
growth with 1 μM (HepG2) - 2.5 μM (Hep3B and PLC/
PRF/5) Regorafenib or Sorafenib, concentrations which
are known to decrease in HCC cell proliferation [19].
Cells were also treated in the absence or presence of
increasing concentrations of hPL. A significant increase
of cell growth was detected in presence of hPL from
3.75 × 107 platelets in all the HCC cell lines, compared
with treatments with Regorafenib or Sorafenib in pres-
ence of FBS. Figure 1A-F shows the time course of these
effects on the three cell lines. In order to exclude a pos-
sible FBS effects on the observed antagonism of cell
growth inhibition due to drug action, PLC/RFP/5 cells
treated or untreated with 2.5 μM Regorafenib were cul-
tured in different FBS concentrations (0-5%) for 48 h in
presence or absence of hPL derived from 3.75 × 107
platelets.
Comparing the growth in these different conditions by
MTT assay, it was clear that increasing the serum con-
centration more than 1% had not significant influence
on PLTs antagonism (Figure 1G). Identical results were
obtained with Sorafenib treatments (data not shown).The concentrations of medium alpha-fetoprotein (AFP),
an HCC cell growth marker, were also measured. We
found that Sorafenib-mediated inhibition of AFP levels
was also antagonized by the presence of hPL (Figure 1H).
Effects of platelet factors on cell signaling
Both Sorafenib and Regorafenib have previously been
shown to cause a decrease in P-ERK levels, consequent
on Raf inhibition. Here, we examined the effects of
2.5 μM Sorafenib or Regorafenib on P-ERK levels in
Hep 3B cells in the absence or presence of hPL from
3.75 × 107 platelets. We found that hPL caused an increase
in P-ERK levels, as well as for P-p38 and P-STAT3 (Ser
and Tyr). By contrast, P-JNK levels were not modified
by the presence or absence of hPL (Figure 2).
Platelet factor antagonism of drug-mediated inhibition of
migration and invasion
Both Sorafenib and Regorafenib can inhibit both HCC cell
migration and invasion through Matrigel membranes. Fur-
thermore, hPL has been shown to stimulate cell motility
[21]. We therefore added hPL to 2.5 μM concentrations of
Sorafenib or Regorafenib that could inhibit both migration
and invasion in Hep3B cells.
We found that hPL antagonized the inhibition by
Sorafenib or Regorafenib on both migration and invasion
(Figure 3A-C). Identical results were found for the other
cell lines (data not shown).
Platelet factor antagonism of drug-mediated induction of
apoptosis
To evaluate the possible platelet factor mechanisms, we
examined their effects on Sorafenib or Regorafenib–
mediated apoptosis, since that is one major aspect of their
growth-inhibitory actions.
The drug induced both an increase in Annexin V
and activation of Caspase 3/7, two separated apoptosis
markers. When hPL were also added to the cell medium
together with drug, a pronounced and significant inhib-
ition in apoptosis induction was found (Figure 4A-B).
These results were confirmed at the protein level with
an increase of survivin, Bcl-xL and P-AKT levels (anti-
apoptotic factors) and a decrease of Bax and Bim levels
(pro-apoptotic factors) in Hep3B cells treated with
2.5 μM Sorafenib or Regorafenib in presence of hPL
from 3.75 × 107 platelets (Figure 4C).
Figure 2 Platelet extracts counteract the inhibitory effects of Sorafenib. A representative Western blot of 2.5 μM Sorafenib action that
inhibits RAF/MEK/ERK signaling in Hep3B cells (to the left of the figure). The same action had been observed by Regorafenib (data not shown).
The presence of hPL from 3.75 × 107 platelets reduced drug effects (to the right) with an increase of P-ERK, P-p38, P-STAT3, consistent with the
induction of cell proliferation. No changes were observed in the phosphorylation levels of JNK.
Figure 3 Platelet antagonism of drug-mediated inhibition of migration and invasion. Hep3B cell line was cultured in 1% FBS medium in
presence of different platelets concentrations or FBS and incubated with 2.5-5 μM Sorafenib (A, C) or Regorafenib (B, C). Results of cell migration
(A, B) and invasion (C) were expressed as percentage of migration (100% representing the completely closed wound) and fold increase over
control invading cell, respectively.
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Figure 4 Platelet extract antagonism of drug-mediated inhibition of apoptosis. Apoptosis assays. On the left are shown examples of the
results obtained using the Muse Annexin V kit (A) or Caspase-3/7 kit (B) to evaluate the percentage of apoptotic PLC/PRF/5 Hep3B cells treated
with 2.5 μM of Regorafenib (A-B) or Sorafenib (A) and cultured whit 3.75 × 107 hPL or equivalent FBS are expressed in the relative graph as the
mean of three independent experiments. On the right the mean of three independent experiments is plotted in the relative graph. The results
are expressed as mean ± SD. ***p < 0.0001. The anti-apoptotic effect of hPL was also evaluated at the molecular level (C). The representative
Western blot shows Hep3B cells treated with 2.5 μM Sorafenib with and without hPL from 3.75 × 107 platelets. hPL caused increased levels of
anti-apoptotic factors (survivin, Bcl-xL, P-AKT) and decreased levels of pro-apoptotic (Bax, Bim) factors.
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cell growth
HCC cell lines were cultured in 1% FBS in presence of dif-
ferent doses of serotonin (1, 10 μM), IGF (50, 100 mg/ml)
and EGF (10, 25 mg/ml) alone and in combination. The
effect on proliferation, evaluated by MTT assay after 48 h,
was significant only with EGF, while serotonin and IGF
were effective only when used in combination. Figure 5A
shows the results obtained whit HepG2 cell line cultured
as described above; in the graphs were plotted the effective
combinations. When Sorafenib 1 μM was added to the
growth factors treatments, IGF and EGF antagonized the
drug inhibition of proliferation; also in this case the effect
was higher when IGF and EGF were used in combination
(Figure 5B).
Discussion
We report here for the first time, the antagonizing
effects of platelet extracts on growth inhibition in sev-
eral HCC cell lines, that was mediated by Sorafenib or
Regorafenib. Both agents were similarly antagonized by
hPL. Furthermore, the previously demonstrated inhib-
ition of AFP secretion by these drugs, was also antago-
nized. A main consequence of each drug is a decrease
in phospho-ERK levels, secondary to Raf inhibition.
hPL antagonized this early consequence of the drug
action, without change in ERK levels. There was also
an early and strong antagonism of the previously notedFigure 5 EGF and IGF counteract the inhibitory effect of Sorafenib. H
concentrations of serotonin, EGF and IGF-I or equivalent FBS (A) or incubat
Sorafenib (B). MTT assay was assessed after 48 h. The results are expressedinhibitory effects of drug on phospho-p38 levels [20],
and similarly for the p38 downstream target, phospho-
STAT3 (Tyr and Ser). These are important molecules
in mediating cell proliferation and play a role in the in-
duction of anti-apoptosis mediators. Both Sorafenib
and Regorafenib are known to increase apoptosis in
treated cells. We found that this apoptosis-induction
was antagonized by addition of hPL to cells that were
treated with each of these two agents, as measured by
both annexin V and caspase 3/7 activation.
Consistent with our findings of increased phospho-
STAT3 levels, we also found an increase in the levels of
anti-apoptotic Bcl-xL and survivin and a decrease in the
levels of pro-apoptotic Bim and Bax, consequent to hPL
action.
Due to the important role of platelets in the metastasis
mechanisms of many tumors [8,21], we evaluated hPL
for a possible role in stimulating cell migration or inva-
sion. We founds that the extracts also antagonized drug-
mediated inhibition of HCC cell migration and invasion
on Matrigel-treated membranes. In other systems, the
targeting of platelets or experimental decrease in their
numbers has been shown to enhance cancer chemother-
apy [22,23].
Platelets are the source of multiple growth factors, cyto-
kines and inflammatory mediators [6].
Included among them are EGF, IGF-I, fibroblast growth
factor (FGF), platelet derived growth factor (PDGF) andepG2 cell line was cultured in 1% FBS medium in presence of different
ed with the same doses of growth factors in presence of 1 μM
as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001.
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alter cancer chemotherapy sensitivity or resistance
[24-30]. Preliminary data, obtained with several growth
factors included in hPL, revealed interesting results
using EGF and IGF-I. Both these factors were able to
antagonized Sorafenib in a proliferation assay, in par-
ticular when used in combination. This growth induc-
tion was more evident than that observed in absence of
drug, suggesting a specific interference of these growth
factors with the inhibitory action of Sorafenib.
Interestingly, the clinical insulin modulator and dia-
betes drug, metformin [26] and the serotonin modulator
Fluoxetine/Prozac that is used in depression treatment
[29,30], each alter chemotherapy sensitivity in cancer
cells. Multiple pathways have been found to be involved in
Sorafenib-mediated growth inhibition, especially apoptosis
and autophagy [19,31,32] as well as others [33-37] and
several cytokines, or cytokine modulators that are pro-
duced by platelets can modulate Sorafenib activity [38].
Since Sorafenib effects have been clinically modest, several
approaches are under way to enhance its actions, either
on its downstream targets, or by adding inhibitors of
parallel pathways in combination therapies [39]. Given
the large number of candidate factors in platelets, the
identification of those responsible for drug resistance is
just beginning. However, FGF, IGF1 and serotonin
would seem to be promising possibilities.
The recent finding that platelet inhibitors reduce hepa-
titis B associated experimental HCC [40] has led to new
interest in the use of aspirin and other platelet inhibitors
in HCC prevention, as in colon cancer prevention [41].
Thrombocytosis has been shown to be a negative prog-
nostic factor for renal, breast, ovary, pancreas and colon
cancers. Therefore, the results from this paper might be
applicable to those tumor types, especially to renal can-
cer, since Sorafenib is also FDA-approved for treatment
of renal cancer.Conclusion
The current results give support to the idea that platelet
inhibitors might also be useful in the drug therapy of
patients with unresectable HCC, provided their platelet
levels and coagulation systems are normal.Abbreviations
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